A CROSS-SECTIONAL OBSERVATIONAL STUDY TO EVALUATE THE EFFICACY OF METHYLENE BLUE IN THE TREATMENT OF HYPOXIC COVID-19 PATIENTS

NARENDER SAYINI; PADMA RACHARLA

doi:10.22159/ijpps.2025v17i3.53238

Authors

NARENDER SAYINI Department of Pulmonology GGH, Karimnagar, Telangana-505001, India https://orcid.org/0009-0000-6440-0837
PADMA RACHARLA Department of General Medicine, GGH, Karimnagar, Telangana-505001, India

DOI:

https://doi.org/10.22159/ijpps.2025v17i3.53238

Keywords:

Acute respiratory distress syndrome, Hypoxemia, Respiratory rate

Abstract

Objective: The primary objective of this study is to evaluate the effectiveness of Methylene Blue (MB) in reducing hypoxia in COVID-19 patients.

Methods: A retrospective cross-sectional observational record-based study was conducted at Sai Krishna Multi-Specialty Hospital, Karimnagar, Telangana, over four months with 100 case sheets. A paired equal variance T-test was used to compare the pre-and post-treatment levels of SpO₂ and respiratory rate among the hypoxic patients.

Results: Out of 100 case sheets examined, about 70 patients were between the age groups of 45 to 54 years, 58 were males and 42 were females. The mean SPO₂ before treatment was 71.47% compared with day 3 values of SPO_2, which is 77.76%, and there was a significant improvement in the mean saturation levels with a P value less than 0.0001. There was a significant improvement in the mean respiratory rate, which was 26.92+0.85 at baseline before treatment, 23.93+0.90 on Day 3, and 21.42+1.27 on Day 7 after treatment with methylene blue and the P value is less than 0.0001.

Conclusion: This study concludes that Methylene blue intervention in COVID-related acute respiratory distress syndrome avoids the devastating consequences and improves patients’ condition by reducing hypoxemia and respiratory distress.

Downloads

Download data is not yet available.

References

Rani AS, Madhavi P, Chakradhar T. A retrospective study to evaluate the efficacy of injection augmentin in COVID-19 patients with pneumonia at a Tertiary Care Teaching Hospital Telangana. Int J Pharm Pharm Sci. 2022;14(10):28-31. doi: 10.22159/ijpps.2022v14i10.45730.

Scigliano G, Scigliano GA. Methylene blue in COVID-19. Med Hypotheses. 2021;146:110455. doi: 10.1016/j.mehy.2020.110455, PMID 33341032.

Swarupa K, Sravani M, Karunasree N. Assessment and analysis of adverse events following COVID-19 vaccination among children aged 15-18 y at a Tertiary Care Teaching Hospital Telangana: a prospective observational study. Int J Pharm Pharm Sci. 2023;15(3):15-20. doi: 10.22159/ijpps.2023v15i3.47358.

Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. Pathophysiology of COVID-19: mechanisms underlying disease severity and progression. Physiology (Bethesda). 2020;35(5):288-301. doi: 10.1152/physiol.00019.2020, PMID 32783610.

Mirtaleb MS, Mirtaleb AH, Nosrati H, Heshmatnia J, Falak R, Zolfaghari Emameh RZ. Potential therapeutic agents to COVID-19: an update review on antiviral therapy immunotherapy and cell therapy. Biomed Pharmacother. 2021;138:111518. doi: 10.1016/j.biopha.2021.111518, PMID 33774315.

Sabitha S, Shobana N, Prakash P, Padmanaban S, Sathiyashree M, Saigeetha S. A review of different vaccines and strategies to combat COVID-19. Vaccines (Basel). 2022 May 9;10(5):737. doi: 10.3390/vaccines10050737, PMID 35632493, PMCID PMC9145217.

Shenoy N, Luchtel R, Gulani P. Considerations for target oxygen saturation in COVID-19 patients: are we undershooting? BMC Med. 2020 Aug 19;18(1):260. doi: 10.1186/s12916-020-01735-2, PMID 32814566.

Dabholkar N, Gorantla S, Dubey SK, Alexander A, Taliyan R, Singhvi G. Repurposing methylene blue in the management of COVID-19: mechanistic aspects and clinical investigations. Biomed Pharmacother. 2021 Oct;142:112023. doi: 10.1016/j.biopha.2021.112023, PMID 34399199.

OZ M, Lorke DE, Hasan M, Petroianu GA. Cellular and molecular actions of methylene blue in the nervous system. Med Res Rev. 2011 Jan;31(1):93-117. doi: 10.1002/med.20177, PMID 19760660.

Hepburn J, Williams Lockhart S, Bensadoun RJ, Hanna R. A novel approach of combining methylene blue photodynamic inactivation photobiomodulation and oral ingested methylene blue in COVID-19 management: a pilot clinical study with 12-month follow-up. Antioxidants (Basel). 2022 Nov 8;11(11):2211. doi: 10.3390/antiox11112211, PMID 36358582.

Chuang ST, Papp H, Kuczmog A, Eells R, Condor Capcha JM, Shehadeh LA. Methylene blue is a nonspecific protein-protein interaction inhibitor with potential for repurposing as an antiviral for COVID-19. Pharmaceuticals (Basel). 2022 May 18;15(5):621. doi: 10.3390/ph15050621, PMID 35631447.

Cagno V, Medaglia C, Cerny A, Cerny T, Zwygart AC, Cerny E. Methylene blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitro. Sci Rep. 2021 Jul 12;11(1):14295. doi: 10.1038/s41598-021-92481-9, PMID 34253743.

Ascha M, Bhattacharyya A, Ramos JA, Tonelli AR. Pulse oximetry and arterial oxygen saturation during cardiopulmonary exercise testing. Med Sci Sports Exerc. 2018 Oct;50(10):1992-7. doi: 10.1249/MSS.0000000000001658, PMID 29771822.

Torp KD, Modi P, Pollard EJ. Pulse oximetry. In: Treasure Island, (FL): Stat Pearls Publishing; 2023 Jul 30. p. 2024.

Miller DJ, Capodilupo JV, Lastella M, Sargent C, Roach GD, Lee VH. Analyzing changes in respiratory rate to predict the risk of COVID-19 infection. Plos One. 2020 Dec 10;15(12):e0243693. doi: 10.1371/journal.pone.0243693, PMID 33301493.

Polidoro RB, Hagan RS, DE Santis Santiago R, Schmidt NW. Overview: systemic inflammatory response derived from lung injury caused by SARS-CoV-2 infection explains severe outcomes in COVID-19. Front Immunol. 2020;11:1626. doi: 10.3389/fimmu.2020.01626, PMID 32714336.

Hamidi Alamdari D, Hafizi Lotfabadi S, Bagheri Moghaddam A, Safari H, Mozdourian M, Javidarabshahi Z. Methylene blue for treatment of hospitalized COVID-19 patients: a randomized controlled open-label clinical trial phase 2. Rev Invest Clin. 2021;73(3):190-8. doi: 10.24875/RIC.21000028, PMID 34019535.

Huang C, Wang Y, LI X, Ren L, Zhao J, HU Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5, PMID 31986264.

Meng Y, WU P, LU W, Liu K, MA K, Huang L. Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan China: a retrospective study of 168 severe patients. Plos Pathog. 2020 Apr 28;16(4):e1008520. doi: 10.1371/journal.ppat.1008520, PMID 32343745.

Bwire GM. Coronavirus: why men are more vulnerable to COVID-19 than Women? SN Compr Clin Med. 2020;2(7):874-6. doi: 10.1007/s42399-020-00341-w, PMID 32838138.

Sanei ZS, Shahrahmani F, Khaleghi Manesh B, Hamidi Alamdari D, Mehrad Majd H, Mavaji Darban B. Methylene blue for COVID-19 ARDS: insights from a randomized clinical trial. Naunyn Schmiedebergs Arch Pharmacol. 2024 Aug 29. doi: 10.1007/s00210-024-03371-6, PMID 39207597.

Zhukhovitsky V, Shevlyagina N, Zubasheva M, Russu L, Gushchin V, Meerovich G. Infectivity and morphology of bovine coronavirus inactivated in vitro by cationic photosensitizers. Viruses. 2022 May 15;14(5):1053. doi: 10.3390/v14051053, PMID 35632792.

Yella SH, Yella SS, Sasanka KS, Thangaraju P. Does methylene blue satisfy an option in COVID-19 ARDS? Infect Disord Drug Targets. 2022;22(6):e170322202339. doi: 10.2174/1871526522666220317155947, PMID 35301956.